Submission of Financial Results for the Quarter and Year ended on 31st March 2026
Submission of Outcome of board meeting and Financial Results for the quarter and year ended on 31st March 2026
Approval of Audited Results for the Quarter and Year ended on March 31, 2026
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanySkybiotech Healthcare Ltd 2CIN NO.L17100MH1983PLC031114 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0.00 4Highest Credit Rating during the previous FY NA 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: NISHI JAIN Designation: COMPANY SECRETARY AND COMPLIANCE OFFICER EmailId: kapilcotexlimited@yahoo.co.in Name of the Chief Financial Officer: PRAKASHCHANDRA RATHI Designation: CFO AND DIRECTOR EmailId: rathiprakashchandra@yahoo.in Date: 30/04/2026 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.
Certificate under Reg. 74(5) of SEBI (DP) Regulation, 2018 received from RTA
Intimation of Trading window closure to consider and approve Audited Financials for the Quarter and year ended on 31st March 2026
Submission of Un-Audited Financial Results for the Quarter ended on 31st December, 2025
Outcome of Board Meeting to Considered and Approved Un-Audited Financials for the Quarter ended on 31st December, 2025
Approval of Unaudited Financial Results for the Quarter ended on 31st December, 2025
Compliance certificate Under Reg. 74(5) of SEBI (DP) Regulation, 2018 for the quarter ended on 31st December, 2025
| Particulars | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 2.39 | 1.60 | 2.52 | 1.02 | 2.39 | 1.92 | 0.96 | 1.83 |
| YOY Revenue Growth % | - | - | - | - | 0% | 19.51% | -61.82% | 79.73% |
| Other Income | 0.03 | 0.04 | 0.15 | -0.18 | 0.03 | 0.04 | 0.08 | 0.15 |
| Total Income | 2.42 | 1.64 | 2.67 | 0.83 | 2.42 | 1.96 | 1.04 | 1.98 |
| Total Expenses + | 2.44 | 1.83 | 3.08 | 2.02 | 2.44 | 2.27 | 1.53 | 2.84 |
| Cost of Materials Consumed | 1.24 | 0.47 | 0.86 | 0.91 | 1.24 | 0.33 | 0.55 | 0.97 |
| Employee Benefit Expense | 0.39 | 0.37 | 0.66 | 0.42 | 0.39 | 0.57 | 0.36 | 0.43 |
| Other Expenses | 0.84 | 0.96 | 0.87 | 0.89 | 0.84 | 0.64 | 0.49 | 0.94 |
| Operating Profit | -0.05 | -0.23 | -0.56 | -1.00 | -0.05 | -0.35 | -0.56 | -1.01 |
| OPM % | -2.2% | -14.3% | -22.3% | -98.2% | -2.2% | -18.2% | -58.5% | -55% |
| Profit Before Tax + | -0.02 | -0.19 | -0.41 | -1.18 | -0.02 | -0.31 | -0.48 | -0.85 |
| Tax Expense | 0.00 | 0.06 | -0.02 | -0.10 | 0.00 | 0.00 | 0.00 | -0.55 |
| Tax % | - | - | - | - | - | - | - | - |
| Profit After Tax | -0.02 | -0.25 | -0.39 | -1.08 | -0.02 | -0.31 | -0.48 | -0.30 |
| EPS (Basic) | 0.25 | 5.46 | -3.06 | -13.68 | 0.25 | -1.29 | -1.29 | -2.96 |
| Particulars | Mar 2026 | Mar 2025 |
|---|---|---|
| Revenue from Operations | 7.10 | 7.05 |
| YOY Revenue Growth % | 0.65% | - |
| Other Income | 0.31 | 0.38 |
| Total Income | 7.40 | 7.43 |
| Total Expenses + | 9.07 | 9.86 |
| Cost of Materials Consumed | 3.09 | 3.67 |
| Employee Benefit Expense | 1.76 | 1.96 |
| Other Expenses | 2.90 | 3.72 |
| Operating Profit | -1.97 | -2.81 |
| OPM % | -27.8% | -39.8% |
| Profit Before Exceptional | -1.67 | -2.43 |
| Exceptional Items | 0.00 | 0.00 |
| Profit Before Tax + | -1.67 | -2.43 |
| Tax Expense | -0.55 | -0.06 |
| Tax % | - | - |
| Profit After Tax | -1.12 | -2.37 |
| EPS (Basic) | -6.70 | -14.19 |
| Particulars | Mar 2026 | Mar 2025 |
|---|---|---|
| ASSETS | ||
| Non-Current Assets + | 18.12 | 18.18 |
| Property, Plant & Equipment | 8.37 | 8.85 |
| Capital Work in Progress | 0.00 | 0.00 |
| Non-Current Investments | 2.24 | 2.46 |
| Goodwill | 3.13 | 3.13 |
| Other Intangible Assets | 0.04 | 0.05 |
| Current Assets + | 1.33 | 1.92 |
| Inventories | 0.80 | 1.59 |
| Trade Receivables | 1.11 | 0.42 |
| Cash and Cash Equivalents | -0.59 | -0.27 |
| Current Investments | 0.00 | 0.00 |
| LIABILITIES & EQUITY | ||
| Total Equity | 9.25 | 10.54 |
| Equity Share Capital | 1.92 | 1.92 |
| Other Equity | 6.08 | 7.07 |
| Non-Current Liabilities | 8.25 | 7.01 |
| Current Liabilities | 1.94 | 2.55 |
| Total Liabilities | 10.19 | 9.56 |
| Particulars | Mar 2026 | Mar 2025 |
|---|---|---|
| Cash from Operating Activities | -1.52 | -1.04 |
| Cash from Investing Activities | 0.02 | -9.63 |
| Cash from Financing Activities | 1.17 | 1.24 |
| Net Increase/Decrease in Cash | -0.33 | -9.43 |